Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$7.50
0.223.02%
Pre-Market: 7:44 AM EDT
Comments
Loading...
Immunome Analyst Ratings and Price Targets | NASDAQ:IMNM | Benzinga
Immunome Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Immunome Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Wedbush
Stephens & Co.
Guggenheim
LifeSci Capital
Piper Sandler
1calculated from analyst ratings
Analyst Ratings for Immunome
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/20/2025 | Buy Now | — | Wedbush | David Nierengarten63% | $33 → $33 | Reiterates | Outperform → Outperform | Get Alert |
| 03/20/2025 | Buy Now | — | Stephens & Co. | Sudan Loganathan31% | $30 → $30 | Reiterates | Overweight → Overweight | Get Alert |
| 03/20/2025 | Buy Now | — | Guggenheim | Michael Schmidt56% | $35 → $25 | Maintains | Buy | Get Alert |
| 03/11/2025 | Buy Now | — | LifeSci Capital | — | → $20 | Initiates | → Outperform | Get Alert |
| 11/14/2024 | Buy Now | — | Piper Sandler | Biren Amin39% | $23 → $21 | Maintains | Overweight | Get Alert |
| 11/08/2024 | Buy Now | — | Stephens & Co. | Sudan Loganathan31% | → $30 | Initiates | → Overweight | Get Alert |
| 10/25/2024 | Buy Now | — | Wedbush | David Nierengarten63% | $33 → $33 | Reiterates | Outperform → Outperform | Get Alert |
| 08/13/2024 | Buy Now | — | Piper Sandler | Biren Amin39% | $27 → $23 | Maintains | Overweight | Get Alert |
| 08/13/2024 | Buy Now | — | Wedbush | David Nierengarten63% | $33 → $33 | Reiterates | Outperform → Outperform | Get Alert |
| 05/31/2024 | Buy Now | — | Piper Sandler | Biren Amin39% | → $27 | Initiates | → Overweight | Get Alert |
| 04/30/2024 | Buy Now | — | JP Morgan | Brian Cheng37% | → $24 | Initiates | → Overweight | Get Alert |
| 04/15/2024 | Buy Now | — | Guggenheim | Michael Schmidt56% | → $35 | Initiates | → Buy | Get Alert |
| 04/01/2024 | Buy Now | — | Wedbush | David Nierengarten63% | $27 → $33 | Maintains | Outperform | Get Alert |
| 01/23/2024 | Buy Now | — | Wedbush | David Nierengarten63% | $12 → $19 | Maintains | Outperform | Get Alert |
| 12/19/2023 | Buy Now | — | Wedbush | David Nierengarten63% | → $12 | Initiates | → Outperform | Get Alert |
| 03/20/2023 | Buy Now | — | Cantor Fitzgerald | Pete Stavropoulos43% | → $8 | Reiterates | → Overweight | Get Alert |
| 03/17/2023 | Buy Now | — | Chardan Capital | Matthew Barcus55% | $9 → $8 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Immunome (IMNM) stock?
The latest price target for Immunome (NASDAQ:IMNM) was reported by Wedbush on March 20, 2025. The analyst firm set a price target for $33.00 expecting IMNM to rise to within 12 months (a possible 340.00% upside). 13 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Immunome (IMNM)?
The latest analyst rating for Immunome (NASDAQ:IMNM) was provided by Wedbush, and Immunome reiterated their outperform rating.
When was the last upgrade for Immunome (IMNM)?
There is no last upgrade for Immunome
When was the last downgrade for Immunome (IMNM)?
There is no last downgrade for Immunome.
When is the next analyst rating going to be posted or updated for Immunome (IMNM)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Immunome, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Immunome was filed on March 20, 2025 so you should expect the next rating to be made available sometime around March 20, 2026.
Is the Analyst Rating Immunome (IMNM) correct?
While ratings are subjective and will change, the latest Immunome (IMNM) rating was a reiterated with a price target of $33.00 to $33.00. The current price Immunome (IMNM) is trading at is $7.50, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.